SCHEMBL423287

SCHEMBL423287

Cc1ccc2c(c1)CCC2=O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
HSD17B10 Q99714 1/20 0.59
PARP10 Q53GL7 2/20 0.56
PARP11 Q9NR21 1/20 0.56
HSD17B1 P14061 3/20 0.52
SRD5A1 P18405 2/20 0.51
GRM5 P41594 1/20 0.49
METAP1 P53582 1/20 0.48
MAOA P21397 3/20 0.46
MAOB P27338 3/20 0.46
PRKCI P41743 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
PBRM1 Q86U86 1/20 0.44
PGR P06401 1/20 0.43
PARP1 P09874 1/20 0.43
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29726014 1.00 CASP1 (0.59) CASP1CASP7HSD17B10PARP10PARP11
SCHEMBL27632859 1.00 CASP1 (0.59) CASP1CASP7HSD17B10PARP10PARP11
Hydrochloric Acid SCHEMBL7402731 0.98 CASP1 (0.57) CASP1CASP7HSD17B10PARP10PARP11
Acetic Acid SCHEMBL27953675 0.91 CASP1 (0.50) CASP1CASP7HSD17B10PARP10PARP11
SCHEMBL1027718 0.88 MAOA (0.61) CASP1CASP7HSD17B10PARP10PARP11
SCHEMBL7916500 0.88 MAOA (0.59) CASP1CASP7HSD17B10PARP10PARP11
Dimethylformamide SCHEMBL7844770 0.88 CASP1 (0.47) CASP1CASP7HSD17B10PARP10PARP11
SCHEMBL7435588 0.84 METAP1 (0.60) PARP10PARP11SRD5A1METAP1MAOA
SCHEMBL1747435 0.84 HSD17B1 (0.69) CASP1CASP7HSD17B10PARP10PARP11
SCHEMBL19422232 0.84 PARP10 (0.55) PARP10PARP11SRD5A1METAP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861113-B Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2022-12-06 CN claimed
CN-113861113-A Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2021-12-31 CN claimed
US-10043978-B2 Organic semiconductor formulations FLEXTERRA, INC. (US) 2018-08-07 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
EP-4098670-B1 BIMODAL POLY(ETHYLENE-CO-1-ALKENE) COPOLYMER DOW GLOBAL TECHNOLOGIES LLC (US) 2026-05-13 EP disclosed
US-20260001977-A1 BIMODAL POLY(ETHYLENE-CO-1-ALKENE) COPOLYMER DOW GLOBAL TECHNOLOGIES LLC (US) 2026-01-01 US disclosed
US-12441748-B2 Metal-ligand complexes DOW GLOBAL TECHNOLOGIES LLC (US) 2025-10-14 US disclosed
WO-2025101264-A1 MULTIMODAL POLYETHYLENE COMPOSITIONS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-05-15 WO disclosed
CN-113748140-B Metal-ligand complexes 陶氏环球技术有限责任公司 2025-03-11 CN disclosed
US-20250066357-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-02-27 US disclosed
WO-2025034361-A1 MULTIMODAL POLYETHYLENE COMPOSITIONS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-02-13 WO disclosed
US-20250009924-A1 Indane Derivatives for Malodor Counteraction FIRMENICH SA (CH) 2025-01-09 US disclosed
US-5877218-A PARKINSON'S DISEASE; ANTIEPILEPSY AGENTS; ANTICONVULSANTS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1999-03-02 US disclosed
US-5877221-A TREATING DEMENTIA TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1999-03-02 US disclosed
EP-0662971-B1 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM RHONE POULENC RORER SA (FR) 1998-05-13 EP disclosed
US-5677306-A ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS RHONE-POULENC RORER S.A. (FR) 1997-10-14 US disclosed
US-5639913-A TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1997-06-17 US disclosed
EP-0662971-A1 DERIVATIVES OF 5H,10H-IMIDAZO 1,2-a]INDENO 1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM Aventis Pharma S.A. (FR) 1995-07-19 EP disclosed
WO-1994007893-A1 DERIVATIVES OF 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1994-04-14 WO disclosed
EP-0240859-B1 LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1993-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009924-A1 Indane Derivatives for Malodor Counteraction MAL2, MTNR1A, LPO CASP1 3855/4885CASP7 4420/4885HSD17B10 712/4885
US-20250066357-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C CASP1 3217/4885CASP7 2841/4885HSD17B10 2047/4885
US-12441748-B2 Metal-ligand complexes ARL1, CRKL, SAAL1 CASP1 3590/4885CASP7 3138/4885HSD17B10 4162/4885
US-20260001977-A1 BIMODAL POLY(ETHYLENE-CO-1-ALKENE) COPOLYMER EIF2AK1, ASH2L, SMARCC1 CASP1 1809/4885CASP7 2689/4885HSD17B10 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.